Art. -Nr.: HY-104048

QC6352

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

QC6352 is an orally active KDM4 inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits KDM4 different isoforms with IC₅₀s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against KDM5 with an IC₅₀ of 750 nM (KDM5B).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.13%
CAS. Nr.: 1851373-36-8
Formel: C₂₄H₂₅N₃O₂
Molecular Weight:387.47

Speicherung:

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

QC6352 Chemical Structure

CAS. Nr.: 1851373-36-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

KDM4

KDM5B

750 nM (IC₅₀)

KDM4A

104 nM (IC₅₀)

KDM4B

56 nM (IC₅₀)

KDM4C

35 nM (IC₅₀)

KDM4D

104 nM (IC₅₀)

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Breast carcinoma cell	IC₅₀	5 nM Compound: 6; QC6352	Cytotoxicity against HER2-positive patient-derived breast cancer organoid model BR0869f after 5 days by Celltiter-Glo luminescent cell viability assay Cytotoxicity against HER2-positive patient-derived breast cancer organoid model BR0869f after 5 days by Celltiter-Glo luminescent cell viability assay	[PMID: 28835804]
Colon carcinoma cell	IC₅₀	13 nM Compound: 6; QC6352	Cytotoxicity against patient-derived colon cancer organoid model SU60 after 96 to 168 hrs by Celltiter-Glo luminescent cell viability assay Cytotoxicity against patient-derived colon cancer organoid model SU60 after 96 to 168 hrs by Celltiter-Glo luminescent cell viability assay	[PMID: 28835804]
IMR-90	EC₅₀	>30000 nM Compound: 6; QC6352	Cytotoxicity against human IMR90 cells Cytotoxicity against human IMR90 cells	[PMID: 28835804]
KYSE-150 cell line	EC₅₀	3.5 nM Compound: 6; QC6352	Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay	[PMID: 28835804]
KYSE-150 cell line	EC₅₀	3.5 nM Compound: 14; QC6352	Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay	[PMID: 35838529]

In Vitro

QC6352 is a potent KDM4C inhibitor with an IC₅₀ of 35±8 nM^[1]. In a concentration-dependent manner QC6352 dramatically reduces the sphere-forming capacity of BCSC1 and BCSC2. QC6352 blocks proliferation and self-renewal of BCSCs. As shown by western blot analysis the protein levels of (Epidermal growth factor receptor) EGFR are reduced in both BCSC1 and BCSC2 upon treatment with QC6352^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

QC6352 strongly affects tumor growth and final tumor weight of both BCSC1 and BCSC2 xenografts. Treatment with QC6352 is well tolerated and does not affect body weight of the mice. Results demonstrate that treatment with the KDM4 inhibitor QC6352 blocks BCSC xenograft tumor growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1851373-36-8
Appearance Solid
Molecular Weight 387.47
Formel C₂₄H₂₅N₃O₂
Color Light yellow to yellow
SMILES

O=C(C1=C(NC[C@@H]2CCCC3=C2C=CC(N(C)C4=CC=CC=C4)=C3)C=NC=C1)O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Publications (11)

All

Sort by:

Journal Impact Factor

Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Mol Cell

Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress. [Abstract]

2021 May 20;81(10):2148-2165.e9. PMID: 33743195
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
J Med Chem

Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate. [Abstract]

2024 Mar 28;67(6):4525-4540. PMID: 38294854
RSC Med Chem

Exploration of hydrazine-based small molecules as metal chelators for KDM4 inhibition. [Abstract]

2025 Jul 1. PMID: 40656835
Clin Exp Med

Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]

2025 Nov 25;26(1):33. PMID: 41286164
BMC Bioinformatics

2026 Feb 19.
bioRxiv

Automated Image-Based Profiling of Pluripotent Stem Cell Colonies. [Abstract]

2025 Sep 16:2025.09.16.676586. PMID: 41000952
bioRxiv

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers. [Abstract]

2025 Feb 5:2025.01.31.635709. PMID: 39975048
bioRxiv

Distinct H3K9me3 heterochromatin maintenance dynamics govern different gene programs and repeats in pluripotent cells. [Abstract]

2024 Sep 16:2024.09.16.613328. PMID: 39345615
bioRxiv

2022 May 14.491739.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 16.67 mg/mL (43.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5808 mL

12.9042 mL

25.8084 mL

5 mM

0.5162 mL

2.5808 mL

5.1617 mL

10 mM

0.2581 mL

1.2904 mL

2.5808 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (4.31 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (4.31 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (4.31 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (25.81 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

Cells are detached by Accutase and counted. 1×10³ single BCSC1 and BCSC2 cells are seeded as triplicates in 50% Matrigel into individual wells of 24-well ultra-low attachment plates in serum-free MSC medium. After 7 days, spheres over 50 μm diameter are counted for QC6352- and QC6688-treated and control cells and spheres over 20 μm diameter are counted for paclitaxel-treated and control cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice: When tumors reach a palpable size of 3 mm³, mice are treated with vehicle (control) or QC6352. The inhibitor is administered daily to mice via oral gavage at 10 mg/kg. Control animals receive vehicle only. Animals are monitored twice weekly for weight and tumor growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Chen YK, et al. Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett. 2017 Jul 27;8(8):869-874. [Content Brief]

[2]. Metzger E, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017 Sep 7. pii: canres.1754. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5808 mL	12.9042 mL	25.8084 mL	64.5211 mL
	5 mM	0.5162 mL	2.5808 mL	5.1617 mL	12.9042 mL
	10 mM	0.2581 mL	1.2904 mL	2.5808 mL	6.4521 mL
	15 mM	0.1721 mL	0.8603 mL	1.7206 mL	4.3014 mL
	20 mM	0.1290 mL	0.6452 mL	1.2904 mL	3.2261 mL
	25 mM	0.1032 mL	0.5162 mL	1.0323 mL	2.5808 mL
	30 mM	0.0860 mL	0.4301 mL	0.8603 mL	2.1507 mL
	40 mM	0.0645 mL	0.3226 mL	0.6452 mL	1.6130 mL

Keywords

QC6352

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

QC6352

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Chemical Probe Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) QC6352

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

QC6352

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Chemical Probe Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) QC6352

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

QC6352 Related Classifications

HY-104048 Related Classifications